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Dual regulation of the LDL receptor—Some clarity
and new questions
Upregulation of the expression of the LDL receptor (LDLR) gene does not always lead to an increase in the LDLR protein.
While the mRNA expression of the LDLR and the newly studied proprotein convertase PCSK9 are coordinately upregulated
in absence of sterols, the latter proteinase apparently enhances the degradation of the LDLR protein.The discovery of the LDLR identified the s
major pathway by which LDL is cleared t
ffrom the bloodstream. Deciphering the
cell and molecular biology of the recep- p
Gtor remains the centerpiece of our un-
derstanding of cholesterol homeostasis. p
iHowever, despite its centrality, the LDLR
story still contains paradoxes. Two a
tstudies contribute valuable new clues
and raise new questions about PCSK9, t
ca novel player in this pathway (Rashid et
al., 2005; Cohen et al., 2005). t
GThe LDLR gene is regulated by the290terol-responsive element binding pro- s
tein-2 (SREBP-2). This transcription
actor is present in the ER as an inactive u
Lrecursor, which, upon transport to the
olgi, is cleaved in tandem by the pro- t
Lrotein convertase SKI-1/S1P and the
ntramembranous metalloprotease S2P, e
gllowing the N-terminal fragment to en-
er the nucleus and upregulate transcrip- t
rion of the LDLR and other genes in the
holesterol pathway. The transport of u
he proSREBP-2-SCAP complex to the
olgi is inhibited by sterols, and this ttep is derepressed by “statins,” inhibi-
ors of cholesterol synthesis that also
pregulate the mRNA levels of the
DLR. Yet, despite the upregulation of
he LDLR mRNA, the abundance of the
DLR protein is not increased in the liv-
rs of statin-treated animals. This sug-
ests that there may be posttransla-
ional mechanisms that independently
egulate LDLR protein abundance (Fig-
re 1).
Two years ago, two natural point mu-
ations, S127R and F216L, in the proteinCELL METABOLISM : MAY 2005
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Figure 1. Regulation of the LDL receptor
Both the LDL receptor (LDLR) and PCSK9 genes are positively regulated by the nuclear form of SREBP-2
N(nSREBP-2). The proteolytic release of nSREBP-2 from the ER is favored under conditions of sterol depletion
tas occurs with statins, drugs that inhibit de novo cholesterol synthesis. Increased expression of the LDLR
mRNA leads to increased synthesis of LDLR protein. However, increased production of PCSK9 paradoxically e
enhances the degradation of LDLR protein. Thus, sterol depletion leads to two opposing effects on LDLR t
protein.
b
nPCSK9 (formerly called “NARC-1”), t
causing autosomal-dominant hypercho- t
lesterolemia, were reported (Abifadel et m
al., 2003). This proteinase had pre- f
viously been shown to be highly ex- f
pressed in liver hepatocytes and small t
intestine in rodents (Seidah et al., 2003). m
Subsequently, other laboratories iden- l
ltified the D374Y Anglo-Saxon mutation
(Timms et al., 2004), as well as six other
mutations (Benjannet et al., 2004). Other b
reports also showed that PCSK9 is a a
sterol-responsive gene (Maxwell et al., (
2003), upregulated by statins (Dubuc et t
al., 2004). c
The immediate question raised by o
these studies was whether or not the c
mutations were a gain or a loss of func- H
tion. Adenovirus-mediated overexpres- d
sion of either wild-type or mutant PCSK9 p
in mice resulted in dramatic reduction of e
LDLR protein in liver and elevated circu- t
lating LDL levels (Benjannet et al., 2004; i
Maxwell and Breslow, 2004; Park et al., L
2004). Conversely, PCSK9-siRNA studies f
in HepG2 cells revealed the reverse ef- t
fect (Benjannet et al., 2004). These re- n
Asults suggested that (1) the normal func-CELL METABOLISM : MAY 2005sion of the PCSK9 is to accelerate the
iurnover of the LDLR and (2) the natural
dutant forms of PCSK9 do this more ef-
tectively. Recent studies support the in-
Aerence that the LDL-elevating muta-
dions in PCSK9 are gain-of-function
mutations resulting in reduced protein
revels of the LDLR (Maxwell and Bres-
ow, 2004; Benjannet et al., 2004).
Indeed, PCSK9-knockout mice exhi-
it w50% reduction in total cholesterol
nd w3-fold increase in hepatic LDLR
Rashid et al., 2005). Most of the choles-
erol reduction is attributable to dramati-
ally accelerated clearance by the LDLR
f LDL and HDL (in mice, the LDLR can
lear a fraction of apoE-containing
DL). In the absence of PCSK9, statins
ramatically upregulate the LDLR and
otently increase LDL clearance (Rashid
t al., 2005), convincingly demonstrating
hat PCSK9 is responsible for the inabil-
ty of these drugs to increase the level of
DLR protein in wild-type animals. The
indings from the Horton lab tie in with
hose of another study in which two
onsense mutations common in African
mericans (w2% combined frequency),eading to w40% reduction in LDL cho-
esterol, were found (Cohen et al., 2005),
trengthening the idea that loss-of-func-
ion mutations in PCKS9 are protective
f LDLR protein levels. While the Y142X
utation would result in protein loss, the
-terminal C679X mutation may affect
he folding/trafficking of the enzyme.
he high frequency of these mutations
nd the haplotype structure of the
eighboring chromosomal regions de-
cribe ancient alleles that may have
een subject to positive selection. This
mplies that there might have been a
rotective consequence (other than ath-
rosclerosis prevention) for upregulating
he LDLR or that these PCSK9 alleles
ould have other functions that might
ave been under positive selection in
frica. There are contradictory data re-
arding the secretion of apoB, the main
polipoprotein of LDL, from livers or
ells expressing wild-type or mutant
orms of PCSK9. In some studies, apoB
ecretion is not affected, while in others
verexpression of PCSK9 increases it.
evertheless, in vivo mice data revealed
hat PCSK9-deficient hepatocytes do
xhibit a small reduction in apoB secre-
ion (Rashid et al., 2005).
Although the LDLR could conceivably
e a substrate of PCSK9, the latter does
ot seem to directly cleave the LDLR,
uggesting that if its enzymatic activity
s indeed essential for the induction of
egradation of this receptor, it is likely
hrough an as yet unidentified substrate.
lternatively, PCSK9 may enhance the
estruction of the LDLR by a nonenzy-
atic mechanism. Still, key questions
emain:
(1) It is not clear whether or how the
natural mutations enhance the en-
zymatic/nonenzymatic activity of
PCSK9. How can we reconcile the
effect of the poorly processed
D374Y zymogen? Why do the mu-
tations result in a dominant pheno-
type? It is unusual for mutations to
increase enzymatic activity unless
they disrupt a negatively regulated
allosteric site (e.g., the GTP site of
glutamate dehydrogenase in pa-
tients with gain-of-function muta-
tions).
(2) The substrates of PCSK9 are un-
known. Identifying liver sub-
strate(s) could be a key step in un-
raveling how PCSK9 affects LDLR
protein abundance.291
P R E V I E W(3) Do the nonsense mutations asso- i
ciated with hypocholesterolemia in L
African subjects result in the loss r
of PCSK9 activity/protein, and if so,
how do we explain the C-terminal A
C679X truncation? Why would 1
PCSK9 nonsense alleles be sub- U
ject to positive selection in Africa? M
(4) What are the mechanisms respon- 2
sible for PCSK9-enhanced degra- c
dation of the LDLR? C
(5) What are the functions of PCSK9 1
in tissues other than liver? M
C
Both the LDLR and PCSK9 mRNAs
are upregulated by SREBP-2, revealing
Stwo opposing effects exerted by the
same initial metabolic signal (cellular A
sterol abundance). It might be that the O
buffering effect of PCSK9 is like the j
Nspring on an accelerator pedal, attenu-
ating the transcriptional effect at the B
Mprotein level. The apparent selectivity of
HPCSK9 for the LDLR in liver suggests
Bthat identifying PCSK9 inhibitors may
pave the way for novel pharmacological C292hnterventions to increase the levels of the
NDLR without affecting other SREBP-2-
Degulated genes.
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